- Marianne J U Novak, clinical research fellow12,
- Sarah J Tabrizi, professor of clinical neurology, honorary consultant neurologist and neurogeneticist 13
- 1National Hospital for Neurology and Neurosurgery, London WC1N 3BG
- 2Wellcome Trust Centre for Neuroimaging, UCL Institute of Neurology, London WC1N 3BG
- 3Department of Neurodegenerative Disease, UCL Institute of Neurology
- Correspondence to: S Tabrizi sarah.tabrizi{at}prion.ucl.ac.uk
- Accepted 8 April 2010
Summary points
Huntington’s disease causes motor, cognitive, and psychiatric impairment
Predictive and diagnostic genetic testing are available through specialist centres
Genetic testing for the disease has many implications for patients and families
The disease currently has no cure, but many therapeutic options exist to improve symptoms
Optimal care usually requires input from a multidisciplinary team
Huntington’s disease is a devastating inherited neurodegenerative disease characterised by progressive motor, cognitive, and psychiatric symptoms. Patients may present with any of these symptoms, and familiarity with the phenotype is therefore important. Chorea and loss of balance are early symptoms that patients notice, although families often notice cognitive or personality changes before this.
Sources and selection criteria
This review is based on our experience of leading (SJT) and working in (MJUN) the multidisciplinary Huntington’s disease clinic at the National Hospital for Neurology and Neurosurgery, supported by an up to date literature review performed using PubMed and a review of the Cochrane database.
The disease occurs in all racial groups but is most common in people of northern European origin. Its prevalence in the Western hemisphere is 7-10/100 000.w1 The mean age of onset of symptoms is 40 years, but juvenile onset (<20 years) and older onset (>70 years) forms are well recognised. The Huntington’s Disease Association (HDA) has records of 6161 adults with symptomatic Huntington’s disease and 541 children with juvenile Huntington’s disease (in England and Wales) at the time of writing. This is a conservative estimate of prevalence because it includes only those people in contact with the HDA, and it suggests that the true prevalence of the disease is higher than previously thought.1
Although relatively uncommon, Huntington’s disease can be devastating for patients and their families. People who are at risk of developing the disease because of a family history face difficult decisions about genetic testing. We review …
Sign in
Personal subscribers, sign in here:
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
The decline in the breast cancer incidence is 1.2% and it is not significant.
Published 10 February 2012
'twas ever thus
Published 10 February 2012
The value of historic human remains
Published 10 February 2012
In Praise of British Literature
Published 10 February 2012
Is real shared decision making possible?
Published 10 February 2012
Most responses
Does anyone understand the government’s plan for the NHS? (17 responses)
Published 17 Jan 2012
Bad medicine: medical nutrition (15 responses)
Published 18 Jan 2012
Shared decision making: really putting patients at the centre of healthcare (7 responses)
Published 27 Jan 2012
Why legislation is necessary for my health reforms (7 responses)
Published 1 Feb 2012
Search for evidence goes on (5 responses)
Published 17 Jan 2012